|
1.Cheng F, Zhao J, Fooksa M, Zhao Z；A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes.；J Am Med Inform Assoc；2016 Jul 2.Chung R, Tyebally S, Chen D, Kapil V, Walker JM, Addison D, Ismail-Khan R, Guha A, Ghosh AK；Hypertensive Cardiotoxicity in Cancer Treatment-Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies-Epidemiology, Incidence, and Pathophysiology.；J Clin Med；2020 Oct 18 3.Shah K, Chan KK, Ko Y-J；A systematic review of post first-line treatments for advanced gastrointestinal stromal tumor (GIST): Direct pairwise meta-analyses and indirect comparisons；J. Clin. Oncol.；2015 4.Custodio JM, Gordi T, Zhong L, Ling KH, Ramanathan S；Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients.；J Clin Pharmacol；2016 Jun 5.Cheng X, Wang J, Lu S, Fan W, Wang W；Aurora kinase A (AURKA) promotes the progression and imatinib resistance of advanced gastrointestinal stromal tumors；Cancer Cell Int.；2021 6.Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, Wang H, Hu B, Coakley EP, Podsadecki TJ, et al.；Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir；Journal of hepatology；2015 7.Feagan BG, Singh S, Lockton S, Hauenstein S, Ohrmund L, Croner LJ, Greenberg GR, Sandborn WJ, Rutgeerts PJ, Vermeire S；Novel infliximab (IFX) and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with crohn's disease (CD)；Gastroenterology；2012 8.Joo J, Mak A, Xiao S, Sleiman P, Hu D, Huntsman S, Eng C, Kan M, Diwadkar A, Hakonarson H, Williams L, Burchard EG, Himes BE；Genome-wide association study of bronchodilator drug response (BDR) in minority children with asthma provides insights into its genetic risk factors；Am. J. Respir. Crit. Care Med.；2021 9.Adenis A, Ray-Coquard I, Italiano A, Chauzit E, Vanseymortier M, Clisant S, Bui Nguyen B, Molimard M, Blay J, Penel N；Phase i dose-escalation study of imatinib mesylate (IM) associated with fixed dose of oral metronomic cyclophosphamide (MC) in selected tumors which may benefit from IM；Ann. Oncol.；2010 10.Erlichman C, Menefee ME, Northfelt DW, Qin R, Reid JM, Lingle WL, Oursler MJ, Reinholz MM, Molina JR, Borad MJ；A phase I trial of the combination of dasatinib and lapatinib；Mol. Cancer Ther.；2009 11.Kwo P, Mantry P, Coakley E, Te H, Vargas H, Brown Jr R, Gordon F, Levitsky J, Terrault N, Burton Jr J, Xie W, Setze C, Badri P, Vilchez RA, Forns X；Results of the phase 2 study M12-999: Interferon-free regimen of ABT-450/R/ABT-267 + ABT-333 + ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection；J. Hepatol.；2014 12.Kiladjian J-J, Heidel FH, Vannucchi AM, Ribrag V, Passamonti F, Hayat A, Conneally E, Martino B, Kindler T, Lipka DB, Acharyya S, Gopalakrishna P, Ide SE, Loechner S, Mu S, Harrison CN；Efficacy, safety, and confirmation of the recommended phase 2 dose of ruxolitinib plus panobinostat in patients with intermediate or high-risk myelofibrosis；Blood；2014 13.Harrison CN, Kiladjian J-J, Heidel FH, Vannucchi AM, Passamonti F, Hayat A, Conneally E, Martino B, Kindler T, Lipka DB, Acharyya S, Gopalakrishna P, Ide S, Liu T, Mu S, Ribrag V；Efficacy, safety, and confirmation of the recommended phase 2 starting dose of the combination of ruxolitinib (RUX) and panobinostat (PAN) in patients (pts) with myelofibrosis (MF)；Blood；2015 14.Khanna D, Huang S, Ye W, Lin C, Jahreis A, Denton C；Relationship of baseline measures to the change in the forced vital capacity in a phase 3 randomized controlled trial of tocilizumab for the treatment of early systemic sclerosis；Am. J. Respir. Crit. Care Med.；2020 15.Reddel HK, Busse WW, Pedersen S, Tan WC, Chen YZ, Jorup C, Lythgoe D, O'Byrne PM；Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study.；Lancet；2017 Jan 14 16.Huang F, Scholl P, Huang DB, MacGregor TR, Vinisko R, Castles MA, Berger F, Robinson P；Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers；J. Clin. Pharmacol.；2011 17.Ierardi E, Giorgio F, Zotti M, Rosania R, Principi M, Marangi S, Della Valle N, De Francesco V, Di Leo A, Ingrosso M, Panella C；Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.；J Clin Pathol；2011 Nov 18.Yu Y, Loi CM, Hoffman J, Wang D；Physiologically Based Pharmacokinetic Modeling of Palbociclib.；J Clin Pharmacol；2017 Feb 19.Albers LJ, Ozdemir V, Marder SR, Raggi MA, Aravagiri M, Endrenyi L, Reist C；Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: A prospective dose-adjusted drug interaction strategy；J. Clin. Psychopharmacol.；2005 20.Aquilante CL, Kiser JJ, Anderson PL, Christians U, Kosmiski LA, Daily EB, Hoffman KL, Hopley CW, Predhomme JA, Schniedewind B, Sidhom MS；Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.；J Clin Pharmacol；2012 Nov 21.Ruxrungtham K, Boyd M, Bellibas SE, Zhang X, Dorr A, Kolis S, Kinchelow T, Buss N, Patel IH；Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.；J Clin Pharmacol；2004 Jul 22.Saruwatari J, Yasui-Furukori N, Niioka T, Akamine Y, Takashima A, Kaneko S, Uno T；Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers；J. Clin. Psychopharmacol.；2012 23.Ogasawara K, MacGorman K, Liu L, Chen J, Carayannopoulos LN, Zhou S, Palmisano M, Li Y；Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.；J Clin Pharmacol；2019 Dec 24.Van Heeswijk RPG, Bourbeau M, Campbell P, Seguin I, Chauhan BM, Foster BC, Cameron DW；Time-dependent interaction between lopinavir/ritonavir and fexofenadine；J. Clin. Pharmacol.；2006 25.Shelton MJ, Cloen D, DiFrancesco R, Berenson CS, Esch A, de Caprariis PJ, Palic B, Schur JL, Buggé CJ, Ljungqvist A, Espinosa O, Hewitt RG；The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone.；J Clin Pharmacol；2004 Mar 26.Upadhyay S, Zack J, Staehr P；Low inter-occasion variabilities in ambrisentan pharmacokinetics following administration alone or co-administration with ritonavir；J. Clin. Pharmacol.；2011 27.Hesse C, Siedler H, Burhenne J, Riedel K-D, Haefeli WE；Fluvoxamine affects sildenafil kinetics and dynamics；J. Clin. Psychopharmacol.；2005 28.Zanardi R, Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J；Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study.；J Clin Psychopharmacol；1998 Dec 29.Greenblatt DJ, Harmatz JS, Ryan MJ, Chow CR；Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety.；J Clin Psychopharmacol；2018 Aug 30.Paydary K, Akamaloo A, Ahmadipour A, Pishgar F, Emamzadehfard S, Akhondzadeh S；N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.；J Clin Pharm Ther；2016 Apr 31.Ochs HR, Greenblatt DJ, Verburg-Ochs B, Labedski L；Chronic treatment with fluvoxamine, clovoxamine, and placebo: interaction with digoxin and effects on sleep and alertness.；J Clin Pharmacol；1989 Jan 32.Kim JW, Yu YS, Choi JY, Lee S, Chang WJ, Choi YJ, Jung SP, Kong S-Y, Sim SH, Lee KS, Park JY, Seo YB, Kim YH, Lee ES, Park KH；RNA sequencing analysis and Tcell receptor repertoire in triplenegative breast cancer (TNBC)；J. Clin. Oncol.；2020 33.Song I, Min SS, Borland J, Lou Y, Chen S, Patel P, Ishibashi T, Piscitelli SC；The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants；J. Clin. Pharmacol.；2011 34.Sekar VJ, Spinosa-Guzman S, De Paepe E, De Pauw M, Vangeneugden T, Lefebvre E, Hoetelmans RMW；Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers；J. Clin. Pharmacol.；2008 35.Vonderheide RH, LoRusso PM, Khalil M, Heath E, Khaira D, Soulieres D, Dorazio P, Mariani GL, Usari T, Domchek SM；Tremelimumab in combination with exemestane as novel immunotherapy for patients with advanced breast cancer；J. Clin. Oncol.；2009 36.Hermann R, Siegmund W, Giessmann T, Westphal K, Weinbrenner A, Hauns B, Reutter F, Lahu G, Zech K, Bethke TD；The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide；J. Clin. Pharmacol.；2007 37.Schöller-Gyüre M, Kakuda TN, Witek J, Akuma SH, De Smedt G, Spittaels K, Vyncke V, Hoetelmans RMW；Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers；J. Clin. Pharmacol.；2013 38.de Zwaan M, Nutzinger DO；Effect of fluvoxamine on total serum cholesterol levels during weight reduction.；J Clin Psychiatry；1996 Aug 39.La Porte C, Verweij-Van Wissen C, Van Ewijk N, Aarnoutse R, Koopmans P, Reiss P, Stek Jr M, Hekster Y, Burger D；Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers；J. Clin. Pharmacol.；2005 40.Park J, Vousden M, Brittain C, McConn DJ, Iavarone L, Ascher J, Sutherland SM, Muir KT；Dose-related reduction in bupropion plasma concentrations by ritonavir；J. Clin. Pharmacol.；2010 41.Souza MCO, Marques MP, Duarte G, Lanchote VL；Pharmacokinetics and Placental Transfer of Bupivacaine Enantiomers in HIV-Infected Parturient Women on Antiretroviral Therapy.；J Clin Pharmacol；2019 Nov 6 42.Schweizer MT, Haugk K, Cheng HH, Maes JL, Dumpit RF, Nelson P, Montgomery RB, Plymate SR, Yu EY；Challenges in enrolling to metastatic castration-resistant prostate cancer (mCRPC) studies that require androgen receptor splice variant (AR-V) positivity；J. Clin. Oncol.；2017 43.Hesse LM, Greenblatt DJ, Von Moltke LL, Court MH；Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers；J. Clin. Pharmacol.；2006 44.Kanda H, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Otani K；Interaction Study between Fluvoxamine and Quazepam；J. Clin. Pharmacol.；2003 45.Zhu L, Brüggemann RJ, Uy J, Colbers A, Hruska MW, Chung E, Sims K, Vakkalagadda B, Xu X, van Schaik RH, Burger DM, Bertz RJ；CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.；J Clin Pharmacol；2017 Feb 46.Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, Hashimoto T, Shiraishi T, Fukami G, Nakazato M, Shirayama Y, Hashimoto K, Iyo M；A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study；J. Clin. Psychopharmacol.；2012 47.Torres A, Ceccato A, Ferrer M, Gabarrus A, Sibila O, Cilloniz C, Mendez R, Menendez R, Bermejo-Martin J, Niederman MS；Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia.；J Clin Med；2019 Sep 13 48.Dilger K, Fux R, Röck D, Mörike K, Gleiter CH；Effect of high-dose metronidazole on pharmacokinetics of oral budesonide and vice versa: A double drug interaction study；J. Clin. Pharmacol.；2007 49.Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fagerås M；Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.；Lancet Respir Med；2018 Feb 50.Alcalai R, Hirsh-Rokach B, Shai E, Lotan A, Ritter A, Varon D, Spectre G；Differential impact of SSRIs on platelet response to clopidogrel: A randomized, double-blind, crossover trial；Eur. Heart J.；2013 51.Graham EM, Martin RH, Buckley JR, Zyblewski SC, Kavarana MN, Bradley SM, Alsoufi B, Mahle WT, Hassid M, Atz AM；Corticosteroid therapy in neonates undergoing cardiopulmonary bypass: A randomized controlled trial；Circulation；2018 52.Livia C, Crespo-Diaz R, Yamada S, Singh RD, Vadhana D, Siddharthan M, Arrell K, Stalboerger P, Witt T, Rihal M, Rihal C, Terzic A, Behfar A；Innate immune response modulation improves outcomes after acute myocardial infarction；Circulation；2017 53.Sekar V, Verloes R, Meyvisch P, Spittaels K, Akuma SH, De Smedt G；Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers；J. Hepatol.；2010 54.Graham EM, Martin RH, Buckley JR, Zyblewski SC, Kavarana MN, Bradley SM, Alsoufi B, Mahle WT, Hassid M, Atz AM；Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass: RandomizedControlled Trial.；J Am Coll Cardiol；2019 Aug 6 55.Graham EM, Martin RH, Buckley JR, Zyblewski SC, Kavarana MN, Bradley SM, Alsoufi B, Mahle WT, Hassid M, Atz AM；Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass: randomized Controlled Trial；Journal of the American College of Cardiology；2019 56.Di Sabatino A, Ciccocioppo R, Cinque B, Millimaggi D, Morera R, Ricevuti L, Cifone MG, Corazza GR；Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.；Gut；2004 Jan 57.Mencarelli A, Cipriani S, Distrutti E, Palladino G, Ricci P, Francisci D, Baldelli F, Fiorucci S；Anti-HIV protease inhibitors interact with NSAIDS and exacerbate small intestine enteropathy induced by NSAIDS；Gastroenterology；2011 58.Sandborn WJ, Abreu MT, D'Haens GR, Colombel J-F, Vermeire S, Mitchev K, Ernault E, Fedorak RN, Spehlmann M, Wolf DC, Lee SD, Rutgeerts PJ；Predictors of response and remission to certolizumab pegol in patients with Crohn's disease: Data from the WELCOME study；Gastroenterology；2010 59.Hernandez-Breijo B, Chaparro M, Paradela A, De Los Dolores Román Curto I, Cano-Martínez D, Sanmartín-Salinas P, Gisbert JP, Guijarro L；Binding of infliximab to human serum exosomes；Gastroenterology；2015 60.Hernandez-Breijo B, Chaparro M, De Los Dolores Román Curto I, Monserrat J, Cano-Martínez D, Sanmartín-Salinas P, Guerra I, Iborra M, Nuño JLC, Bujanda L, Taxonera C, García-Sánchez V, Marin-Jimenez I, Barreiro-De Acosta M, Vera I, Arranz MDM, López-SanRomán A, Sempere L, Gomollon F, Hinojosa J, Gisbert JP, Guijarro L；Quantification of the concentration of antibodies against infliximab (IFX) in human serum using a pure antibody as calibrator；Gastroenterology；2015 61.Steinhart AHillary, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouin E, Cohen A, Greenberg GR；Combined budesonide and antibiotic therapy for active Crohn's disease: A randomized controlled trial；Gastroenterology；2002 62.Colombel JF, Adedokun OJ, Gasink C, Tang KL, Cornillie F, D'Haens GR, Rutgeerts P, Reinisch W, Sandborn WJ, Hanauer SB；Higher levels of infliximab may alleviate the need of azathioprine comedication in the treatment of patients with Crohn's disease: A sonic post hoc analysis；Gastroenterology；2017 63.Kvasnicka HM, Thiele J, Bueso-Ramos CE, Kamalanabhaiah S, Cortes JE, Kantarjian HM, Verstovsek S；Effects of ruxolitinib therapy on megakaryocyte morphology and inflammatory bone marrow reaction in patients with myelofibrosis；Blood；2013 64.Drusbosky LM, Turcotte M, Castillo P, Vidva R, Gera S, Sauban M, Bhargav P, Deep P, Kapoor S, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, Druker BJ, Cogle CR；Predicting response to CDK4/6 inhibitors and combinations using a computational biology model and its validation: A beat AML project study；Blood；2017 65.Liverpool COVID-19 Interactions (covid19-druginteractions.org) 66.CredibleMeds.org 67.相关药品中、美、日版最新说明书 |
|
|
